GH1 and cancer: General results from SAGhE do not support a carcinogenic effect of rGH, but highlight an unexplained trend in cancer mortality risk in relation to GH dose in patients with previous cancer, and the indication of possible higher risk for bone and bladder cancers and Hodgkin’s lymphoma [6].